199 related articles for article (PubMed ID: 30827933)
1. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma.
Zhong H; Chen J; Cheng S; Chen S; Shen R; Shi Q; Xu P; Huang H; Zhang M; Wang L; Wu D; Zhao W
EBioMedicine; 2019 Mar; 41():167-174. PubMed ID: 30827933
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
3. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers.
Liu Y; Sheng L; Hua H; Zhou J; Zhao Y; Wang B
Technol Cancer Res Treat; 2023; 22():15330338231180785. PubMed ID: 37551117
[No Abstract] [Full Text] [Related]
4. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.
Ren L; Xu J; Li J; Xu T; Yang Y; Wang W; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
Clin Exp Med; 2023 Oct; 23(6):2583-2591. PubMed ID: 36639599
[TBL] [Abstract][Full Text] [Related]
6. A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Cai J; Tian X; Ma S; Zhong L; Li W; Wang L; Guo L; Li Z; Wu Y; Zhong G; Huang H; Xia Z; Xia Y; Liu P; Su N; Fang Y; Zhang Y; Cai Q
Br J Cancer; 2021 Aug; 125(3):402-412. PubMed ID: 34012033
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.
Li X; Xu Q; Gao C; Yang Z; Li J; Sun A; Wang Y; Lei H
Ann Hematol; 2023 Dec; 102(12):3465-3475. PubMed ID: 37615680
[TBL] [Abstract][Full Text] [Related]
8. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
9. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
10. A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Diffuse Large B Cell Lymphoma.
Wang Z; Bao Y; Xu Z; Sun Y; Yan X; Sheng L; Ouyang G
J Inflamm Res; 2024; 17():1-13. PubMed ID: 38193043
[TBL] [Abstract][Full Text] [Related]
11. Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators.
Chen Y; Xu J; Meng J; Ding M; Guo Y; Fu D; Liu A
Ann Transl Med; 2023 Jan; 11(2):71. PubMed ID: 36819580
[TBL] [Abstract][Full Text] [Related]
12. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
14. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
15. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
16. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; GarcĂa-Conde J
Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
[TBL] [Abstract][Full Text] [Related]
17. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study.
Yang Y; Zhang YJ; Zhu Y; Cao JZ; Yuan ZY; Xu LM; Wu JX; Wang W; Wu T; Lu B; Zhu SY; Qian LT; Zhang FQ; Hou XR; Liu QF; Li YX
Leukemia; 2015 Jul; 29(7):1571-7. PubMed ID: 25697894
[TBL] [Abstract][Full Text] [Related]
18. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
19. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]